fbpx

Hope For Aggressive Form of Leukemia Found in a New Compound

Researchers across the world have been trying to come across an effective treatment for patients having AML (Acute Myeloid Leukemia).  AML is an aggressive form of blood cancer that turns out to be one of the most fatal forms of cancer out there. Every year, around 19,520 cases are registered, and around 10,670 patients die [...]

Researchers across the world have been trying to come across an effective treatment for patients having AML (Acute Myeloid Leukemia).  AML is an aggressive form of blood cancer that turns out to be one of the most fatal forms of cancer out there. Every year, around 19,520 cases are registered, and around 10,670 patients die from the same –as suggested by the American Cancer Society.

A team of researchers at Purdue University are in the process of developing a new drug compound that appears promising in the treatment of aggressive leukemia.  Around 30 percent of the patients with AML tend to have a mutation that is caused by a type of kinase referred to as “FLT3.”  The presence of FLT3 makes cancer highly aggressive.  The introduction of FLT3 inhibitors including Radapt (it received approval by FDA Food & Drug Administration in the United States), have responded well to the treatment.  However, most of the patients making use of the inhibitors tend to relapse because of the secondary mutations occurring in the FLT3.   Moreover, the existing treatments to leukemia have also have not been completely successful in treating the cases.

The team of researchers led by Herman O. Sintim – Professor of Chemistry & Drug Discovery at Department of Chemistry in Purdue University, state that it has developed a series of drug compounds that are known to work effectively not only on AML with FLT3 mutations but also on mutations that are drug-resistant – including the F691L mutation.  Sintim says, “The drug compounds tend to possess a great potential for serving as the next-generation therapeutic treatment for AML in relapsed patients who are no longer responding to the 1st or 2nd-generation FLT3 inhibitors.

The results of the given study were published in the journal named “EBioMedicine.”  The particular research is known to align with the Giant Leaps celebration at Purdue University.  This has made the university highly acclaimed for its global achievements in the field of health.  The results of the given study appear very encouraging.  This is because, while several advancements might have been made in other types of cancer over the past few decades, advancements in the field of AML have been quite gradual. AML –accounting for around one percent of all types of cancers, is known to occur when the blood cells do not differentiate or mature and continue multiplying unchecked.

HOPE RISE With Us!

Our mission is to provide hope for those who have cancer and their loved ones through the use of insight, understanding, and knowledge. Our in-depth repository of up-to-date news, data, and research.

Categories

Copyright © 2019. All Rights Reserved The Cure for Cancer

Receive your FREE eBook on 'Latest Cancer Research Articles' over email TODAY!
We would like to send you cancer relevant emails occasionally! Thanks